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ABSTRACT
Background. Ultrasound-guided breast-conserving sur-
gery (USS) results in a significant reduction in both margin
involvement and excision volumes (COBALT trial).
Objective. The aim of the present study was to determine
whether USS also leads to improvements in cosmetic
outcome and patient satisfaction when compared with
standard palpation-guided surgery (PGS).
Methods. A total of 134 patients with T1–T2 invasive
breast cancer were included in the COBALT trial
(NTR2579) and randomized to either USS (65 patients) or
PGS (69 patients). Cosmetic outcomes were assessed by a
three-member panel using computerized software Breast
Cancer Conservative Treatment cosmetic results (BCCT.-
core) and by patient self-evaluation, including patient
satisfaction. Time points for follow-up were 3, 6, and
12 months after surgery. Overall cosmetic outcome and
patient satisfaction were scored on a 4-point Likert scale
(excellent, good, fair, or poor), and outcomes were ana-
lyzed using a multilevel, mixed effect, proportional odds
model for ordinal responses.
Results. Ultrasound-guided breast-conserving surgery
achieved better cosmetic outcomes, with 20 % excellence
overall and only 6 % rated as poor, whereas 14 % of PGS
outcomes were rated excellent and 13 % as poor. USS also
had consistently lower odds for worse cosmetic outcomes
(odds ratio 0.55, p = 0.067) than PGS. The chance of
having a worse outcome was significantly increased by a
larger lumpectomy volume (ptrend = 0.002); a volume
[40 cc showed odds 2.78-fold higher for a worse outcome
than a volume B40 cc. USS resulted in higher patient
satisfaction compared with PGS.
Conclusion. Ultrasound-guided breast-conserving surgery
achieved better overall cosmetic outcomes and patient
satisfaction than PGS. Lumpectomy volumes[40 cc
resulted in significantly worse cosmetic outcomes.
BREAST CANCER
Breast cancer is the most common form of cancer
amongst women in Western countries, with over one mil-
lion cases diagnosed each year. Over recent decades, less
invasive surgical techniques such as breast-conserving
surgery (BCS) and the sentinel node procedure for axillary
nodal staging have been developed with the aim of pre-
serving healthy breast tissue and healthy lymph nodes,
reducing morbidity, and improving cosmetic outcome, all
without compromising oncological outcomes.1–3
Nevertheless, BCS results in difficulties in obtaining
tumor-free resection margins using a traditional palpation-
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guided procedure for palpable breast cancer, with margin
involvement in up to 41 % of patients. This results in the
need for additional treatment such as radiotherapy boost,
re-excision, or even mastectomy.4–6 These additional
treatments are psychologically stressful and have a nega-
tive impact on the final cosmetic result.7–9
An important secondary goal of BCS is the achievement
of a satisfactory cosmetic outcome, especially since patient
survival rates are improving. A number of studies have
shown that cosmetic outcomes in BCS have a marked
bearing on psychological outcomes. Unfortunately, poor
cosmetic outcomes are still observed in up to 40 % of
patients.10–14 Factors influencing cosmetic outcomes
include the volume of resected breast tissue,15 the site of
the tumor,16,17 postoperative wound complications,18 and
the amount of radiotherapy, including the radiotherapy
boost.18–20 Cosmetic outcomes following BCS are mainly
influenced by excision volumes, with large excision vol-
umes generally resulting in less favorable cosmetic
outcomes.21
The COBALT trial was designed to address these
shortcomings in BCS by comparing ultrasound-guided
surgery (USS) with the standard palpation-guided surgery
(PGS). The oncological results showed a dramatic reduc-
tion in margin involvement, with tumor-involved margins
for the invasive component in 3 % of the USS group
compared with 17 % in the PGS group. Moreover, optimal
excision volume was achieved by using USS, whereas PGS
resulted in excision volumes more than twofold too large.8
Of the 13,000 patients diagnosed in The Netherlands each
year, approximately 9000 patients have palpable breast
cancer, of which 75 % can safely undergo BCS with
adjuvant radiotherapy treatment.22
The improvements attributable to USS may potentially
have a positive impact on the final cosmetic outcomes and
patient satisfaction. The current analysis aims to assess the
cosmetic outcomes and patient satisfaction of USS com-
pared with PGS after 1 year of follow-up.
METHODS
Trial Design and Patient Population
The COBALT trial was performed in accordance with
the Declaration of Helsinki, guidelines for Good Clinical
Practice, and the CONSORT statement.23 Central and local
independent medical Ethics Review Boards of the partici-
pating hospitals approved the study protocol (registered at
http://www.TrialRegister.nl, number NTR2579).24
The COBALT trial was a comparative, two-arm, parallel
group, randomized controlled trial (RCT) undertaken in six
hospitals in The Netherlands between October 2010 and
March 2012. Eligible patients were randomized in a 1:1
ratio to either USS or PGS.25 Patients eligible to participate
in the COBALT trial were diagnosed with an early stage
(T1–T2, N0–N1) palpable invasive breast cancer and were
scheduled to undergo BCS. Women with preoperatively
diagnosed ductal carcinoma in situ, multifocal disease, a
history of neoadjuvant therapy, previous surgical treat-
ment, or radiation therapy of the affected breast were
excluded from the study, while patients who had invasive
carcinoma with limited or extensive carcinoma in situ
diagnosed postoperatively by the pathologist were not
excluded.
Surgical Technique
Although the definition of tumor-free margins used in
the current study was ‘no tumor cells at the margin’, the
aim of both USS and PGS for all surgeons was to achieve
complete tumor removal with surgically feasible healthy
tissue margins of up to 1 cm. The closure of the lumpec-
tomy cavity did not involve oncoplastic surgery techniques,
thus allowing seroma formation.
Calculated Resection Ratios
Excess volume resection was defined as a calculated
resection ratio (CRR) and calculated by dividing the vol-
ume of each specimen by the optimal resection volume,
which is the spherical tumor volume plus an arbitrarily
chosen, surgically feasible, tumor-free resection margin of
1 cm.7,26 In an ideal situation, the specimen volume is
identical to the optimal resection volume and the CRR
equals 1.0.
Patient Follow-Up
Follow-up was performed at 3, 6, and 12 months after
initial surgery and consisted of digital photographs of the
breasts and patient self-evaluation. Digital photographs
consisted of standardized 4-viewpoint pictures (one frontal,
two oblique, and one lateral picture of the breasts, from
neck to waist), and were taken during regular outpatient
clinic visits using a digital camera of at least 5 megapixel
resolution.
Scoring of Cosmetic Outcome and Patient Self-
Evaluation
The COBALT trial used subjective (panel- and self-
evaluation) and objective [Breast Cancer Conservative
Treatment cosmetic results (BCCT.core) software] cos-
metic outcome evaluation techniques. In all these methods,
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cosmetic outcome of the treated breast was compared with
the untreated breast and scored using the 4-point Likert
scale, which classifies outcomes as excellent, good, fair, or
poor. ‘Excellent’ meant identical to the untreated breast
and ‘poor’ indicated a marked difference with the untreated
breast.27 Patients who underwent mastectomy following
primary surgery were scored as ‘poor’ on all three evalu-
ation methods.
Panel Evaluation A three-member panel (one
experienced breast surgeon and two laymen) evaluated
the pictures. None of the panel members had performed
surgery on the patients, and patient information and the
study arm were blinded to the observers. The photographs
were combined into a PowerPoint presentation of 30–90
slides, with each slide displaying four photographs of a
patient at a specific follow-up time point. Breast shape or
contour, breast volume, deformity, nipple position, the
appearance of the surgical scar, skin alterations, and overall
cosmetic outcome were all scored.
Computerized Evaluation: BCCT.core The BCCT.core
has been developed in recent years to facilitate cosmetic
outcome assessment, improve reproducibility and to allow
the comparison of the results from different breast clinics
free of subjective individual scores.28 The software was
used to assess the frontal photographs.
Patient Cosmetic Self-Evaluation Patient self-evaluation
was based on a composite questionnaire that included
questions on symmetry between the two breasts on
different items, including firmness of the breast, nipple
position, breast contour, breast volume, appearance of the
scar, final overall result, and patient satisfaction with the
appearance of the breast.
Statistical Methods
Patient, tumor, and treatment characteristics of both
types of surgery were compared using the Chi squared test,
Fisher’s exact test, or the two-independent sample t test.
Intraclass correlation coefficient (ICC) was calculated to
obtain interobserver reliability between the three panel
members. The estimated consistency of agreement between
the three observers at each follow-up occasion was con-
sidered poor when ICC was \0.40, fair when
0.40 B ICC\ 0.60, good when 0.60 B ICC\ 0.75, and
excellent when 0.75 B ICC\ 1.00.29
All panel members’ scores were combined for each
patient separately at a given follow-up time point by
finding the mean overall cosmetic outcome score and
rounding it to the nearest integer. A multilevel, mixed
effect, proportional odds model for ordinal responses was
used to model the odds of having a worse cosmetic out-
come. Since the outcome was assessed at three different
time points by three different methods of evaluation, each
patient contributed nine outcome measurements, and the
patient was considered as a random effect in the model.
Candidate explanatory variables were study center, type of
surgery, follow-up occasion, method of evaluation, T-sta-
dium, body mass index (BMI; kg/m2), age, re-excision
(yes/no), and boost (yes/no). These variables were con-
sidered as fixed effects in the model, and only those that
were significant were retained in the final model. The effect
of specimen volume on cosmetic outcome was investigated
separately after excluding women who had undergone
mastectomy after the primary surgery. The volume mea-
surements were categorized into two groups (volume of
more or less than 40 cc), and were based on the median
volume. During revision of pathology reports, four speci-
mens were identified with suspicious differences between
volume and weight, and one specimen lacked volume
measurement. Volumes of these specimens were therefore
imputed using specimen weight (twice measured: in the
operation theater and by the pathologist). A separate model
was run to investigate patient satisfaction with the
appearance of their breast. The proportionality assumptions
for all models were checked and fulfilled.
All p values were two-sided and a significance level of
5 % was used. All analyses were performed using STATA
version 13 (StataCorp LP, College Station, TX, USA).
RESULTS
Patient and Tumor Characteristics
A brief overview of patient and tumor characteristics is
provided in Table 1. A complete overview of initial
oncological results can be found in the study by Krekel
et al.8 Mean specimen weight, volume, and CRR were
significantly smaller in the USS group than in the PGS
group (weight: 38 vs. 52 g; volume: 38 vs. 53 cc; and
CRR: 1.0 vs. 1.7; all p\ 0.01). Additional therapy was
more frequently required in the PGS group than in the USS
group (27 % vs. 11 %, p = 0.038) and five patients in the
PGS group with tumor-involved margins underwent a
mastectomy. Total missing data rates were 14 % (18
patients) at 3 and 6 months, and 12 % (14 patients) at
1 year. One patient refused to participate in follow-up, one
patient had major complications due to chemotherapy and
could not participate in follow-up, one patient refused
follow-up after 3 months, and one patient was excluded
from follow-up because she refused radiotherapy. The
remaining missing data points per patient were due to the
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inability to attend the outpatient clinic visit despite several
appointments.
Inter-Rater Reliability for Panel Evaluation
The estimated consistency of agreement between the
three observers was fair for responses on the first follow-up
occasion (ICC 0.59) and good for the next two occasions
(ICC 0.69 at 6 months; ICC 0.68 at 12 months).
Cosmetic Outcome, Including Mastectomies:
Ultrasound-Guided Surgery versus Palpation-Guided
Surgery
Ultrasound-guided surgery resulted in better cosmetic
outcomes than PGS—20 % versus 14 %, respectively, of
the overall responses rated excellent. Only 6 % of the
responses were poor with USS, compared to 13 % with
PGS (Table 2). Overall, a patient had a 45 % reduced
chance of a worse cosmetic outcome with USS compared
with PGS (odds ratio [OR] 0.55, p = 0.067); the odds of
having a worse cosmetic outcome became significantly
greater by 12 months (OR 2.57, p\ 0.001). When con-
sidering various evaluation methods, the odds of reporting
a worse cosmetic outcome were lower for panel- and self-
evaluation than for BCCT.core software. Furthermore, the
odds of having a worse cosmetic outcome were 2.35-fold
higher for T2 tumors than T1 tumors (p = 0.010).
(Table 3)
To elaborate on our findings, in Table 4 we report the
probabilities of scoring the breast as excellent, good, fair,
or poor. For all three evaluation methods, the probability of
an excellent or good score was clearly higher with USS
than with PGS, and the cumulative probabilities of these
responses were 70 versus 56 % for BCCT.core, 81 versus
69 % for panel evaluation, and 78 versus 66 % for patient
self-evaluation, respectively.
TABLE 1 Patient and tumor characteristics
PGS USS p Valuea
Age [mean (95 % CI)] 57.0 (54.6–59.4) 54.4 (51.9–56.8) 0.124
BMI [mean (95 % CI)] 26.6 (25.4–27.8) 26.2 (25.0–27.4) 0.685
Location of carcinoma [n (%)]
Upper outer 48 (70) 31 (48) 0.079
Upper inner 7 (10) 12 (19)
Lower outer 9 (13) 16 (25)
Lower inner 5 (7) 5 (8)
Weight specimen [mean (95 % CI)] 51.9 (43.9–59.9) 37.8 (31.4–44.1) 0.007
Volume specimen [mean (95 % CI)] 53.1 (45.0–61.2) 37.9 (31.2–44.5) 0.004
Diameter tumor [mean (95 % CI)] 2.0 (1.8–2.2) 2.0 (1.8–2.2) 0.983
T-stadium [n (%)]
T1 35 (51) 36 (56) 0.523
T2 34 (49) 28 (44)
CRR [mean (95 % CI)] 1.7 (1.4–2.0) 1.0 (0.9–1.2) \0.001
Additional therapy [n (%)]
None 50 (73) 57 (89) 0.038
Re-excision 3 (4) 1 (2) (0.016 for comparison additional therapy yes/no)
Mastectomy 5 (7) 0 (0)
Boost 11 (16) 6 (9)
PGS palpation-guided surgery, USS ultrasound-guided surgery, CI confidence interval, BMI body mass index
a Chi squared test, Fisher’s exact test, or two independent sample t-tests













PGS palpation-guided surgery, USS ultrasound-guided surgery
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Effect of Volume on Cosmetic Outcome, Mastectomies
Excluded
The volume measurements were categorized into two
groups (volume of more or less than 40 cc). Excision
volumes [40 cc resulted in 2.78 higher odds of having
worse outcome when compared with volumes B40 cc (OR
2.78, p = 0.002). When volume was included in the model
as a covariate, the difference between the two types of
surgery became nonsignificant (OR 1.18, p = 0.574).
However, of the lumpectomies performed with USS, only
20 % had a volume larger than 40 cc, while the figure for
PGS lumpectomies was 56 %. (Table 5)
Patient Satisfaction
After USS, 90 % of patients were very satisfied or sat-
isfied with the appearance of their breasts compared to
80 % with PGS. The chances of being less satisfied were
86 % lower after USS than after PGS, controlled for fol-
low-up time points, T-stadium, and BMI (OR 0.14,
p = 0.006). (Table 2)
TABLE 3 Odds ratios of having worse cosmetic outcome based on
the proportional odds model for ordinal responses
OR (95 % CI) p Value
Excision method
PGS 1 (Ref)
USS 0.55 (0.29–1.04) 0.067
Follow-up, months
3 1 (Ref)
6 1.21 (0.88–1.66) 0.237
12 2.57 (1.86–3.55) \0.001
Evaluation method
BCCT.core 1 (Ref)
Panel 0.56 (0.41–0.77) \0.001
Self-evaluation 0.65 (0.47–0.88) 0.006
T-stadium
T1 1 (Ref)
T2 2.35 (1.23–4.51) 0.010
BMI 1.08 (1.01–1.16) 0.020
OR odds ratio, CI confidence interval, PGS palpation-guided surgery,
USS ultrasound-guided surgery, BCCT.core Breast Cancer Conser-
vative Treatment cosmetic results, BMI body mass index
TABLE 4 Response probabilities of the overall cosmetic outcome at

















T-stadium is fixed at the sample proportions of T-stadium II and BMI
is fixed at the means of BMI
BMI body mass index, PGS palpation-guided surgery, USS ultra-
sound-guided surgery, BCCT.core Breast Cancer Conservative
Treatment cosmetic results
TABLE 5 Odds ratios of having a worse cosmetic outcome based on
the proportional odds model for ordinal responses (women who
underwent mastectomy were excluded)
OR (95 % CI) p Value
Excision method
PGS 1 (Ref)
USS 1.18 (0.67–2.07) 0.574
Follow-up, months
3 1 (Ref)
6 1.25 (0.90–1.72) 0.182
12 2.66 (1.91–3.70) \0.001
Evaluation method
BCCT.core 1 (Ref)
Panel 0.60 (0.44–0.83) 0.002
Self-evaluation 0.71 (0.52–0.97) 0.033
Volume, cc
Category 1 (B40) 1 (Ref)
Category 2 ([40) 2.78 (1.49–5.18) 0.002a
BMI 1.07 (1.01–1.13) 0.018
OR odds ratio, CI confidence interval, PGS palpation-guided surgery,
USS ultrasound-guided surgery, BCCT.core Breast Cancer Conser-
vative Treatment cosmetic results
a Linear trend
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DISCUSSION
Oncological outcomes are the primary endpoints of
BCS; however, in recent years cosmetic outcome has
gained increased interest. The primary results of the
COBALT trial showed that USS significantly reduced
margin involvement, while the amount of healthy breast
tissue excised was smaller. Furthermore, USS resulted in a
reduction of additional treatments and healthcare costs.8,30
The present study showed that USS improves overall
cosmetic outcomes at 1 year following surgery. ‘Excellent’
or ‘good’ outcomes were observed in 72 % of patients who
had undergone USS, and ‘poor’ cosmetic outcomes were
observed in 6 %. Women treated with PGS had a poor
cosmetic outcome twice as often as women who underwent
USS.
Two studies evaluating cosmetic outcomes following
BCS reported ‘excellent’ or ‘good’ scores in 68–93 % of
patients.31,32 These studies were retrospective, in contrast
to the present RCT, and used different evaluation methods
(i.e. single observer evaluation). The 93 % ‘excellent’ or
‘good’ overall cosmetic outcome score was obtained by
patient self-evaluation, the most subjective evaluation
method. The scores obtained with the BCCT.core software
in these studies were similar to the scores obtained in the
present study.
Only one RCT described cosmetic outcomes with
patient self-evaluation 3 years after radio-guided seed
localization (RSL) or wire localization (WL) for nonpal-
pable carcinomas. ‘Excellent’ and ‘good’ scores were
obtained in 80 % and 76 % of patients, with a ‘fair’ and
‘poor’ cosmetic outcome in 24 % and 19 %, respectively.
Excision volumes and reoperations negatively influenced
cosmetic results.33
In our study, patients were ‘very satisfied or satisfied’
with the appearance of their breast in 90 % of cases after
USS and in 80 % after PGS, which is higher than the 83 %
described by Losken et al. after oncoplastic surgery, and
higher than the 87 % after BCS reported by Eichler
et al..34,35
Different studies have shown that the rate of cosmetic
failure is significantly higher if the size of the lump exceeds
[50–70 cm3, regardless of breast size.19,20,36 In the present
study, only 20 % of the volumes were[40 cc in the USS
group compared with 56 % in the PGS group (breast size
was not evaluated in this study). Other factors influencing
cosmetic outcomes included the site of the tumor,16,17
postoperative wound complications,18 and the amount of
radiotherapy, including the radiotherapy boost.18–20 In this
study, none of these factors appeared to be of significant
influence on the overall cosmetic outcome; complication
rates were low but the rate of women receiving boost
radiotherapy was high due to national guidelines.
As a consensus on a gold standard for cosmetic outcome
assessment is currently lacking and clear guidelines for the
assessment of cosmetic outcomes have failed to emerge,
current advice is that a range of objective and subjective
evaluation methods should be used to evaluate the
appearance of the breasts.13,28,37,38 Therefore, the present
study used three different evaluation methods to obtain an
overall cosmetic outcome.
Cosmetic outcome after 1 year seems to be a good pre-
dictor of final cosmetic outcome (although there are long-
term effects of radiotherapy on breast appearance).20,39,40
Studies have reported that patients with moderate or poor
surgical cosmetic outcome (a few months after surgery)
have an increased risk of developing breast shrinkage or
induration in the long-term, and thereby underline the
importance of reducing specimen volumes.21,39
A poor cosmetic outcome may negatively influence
quality of life and could have a marked bearing on the
psychological outcome.10–13 Using an EORTC QLQ-C30
questionnaire, Hau et al. demonstrated that patients with
‘fair’ or ‘poor’ cosmetic outcome after BCS (at both 5 and
10 years follow-up) had significantly worse quality of life
scores.41 These considerations therefore predict that
patients who underwent USS will have a better quality of
life than those who underwent PGS; however, long-term
follow-up of at least 3 years, including assessment of
patient well-being, are expected in the coming years.
CONCLUSIONS
Ultrasound-guided surgery for early-stage invasive
breast cancer is superior to PGS as it significantly lowers
margin involvement rates, the need for additional therapy,
and healthcare costs, and improves overall cosmetic out-
come and patient satisfaction. Overall, ‘excellent’ or
‘good’ cosmetic outcomes were reported for USS and PGS
in 72 and 65 % of cases, respectively. The improvements
in cosmetic results achieved with USS are probably
attributable to reductions in both additional therapy and
excision volumes.
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